What is Bicycle Therapeutics Financial Strength?
Bicycle Therapeutics has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Bicycle Therapeutics did not have earnings to cover the interest expense.
Bicycle Therapeutics's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.56.
As of today, Bicycle Therapeutics's Altman Z-Score is 1.49.
Competitive Comparison of Bicycle Therapeutics's Financial Strength
For the Biotechnology subindustry, Bicycle Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's Financial Strength falls into.
Bicycle Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Bicycle Therapeutics's Interest Expense for the
months ended in Mar. 2024 was $-0.82 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-31.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $38.85 Mil.
Bicycle Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
| Bicycle Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Bicycle Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Bicycle Therapeutics has a Z-score of 1.49, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of 1.49 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics (Bicycle Therapeutics) Business Description
Traded in Other Exchanges
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Executives
| Nigel Crockett |
officer: Chief Business Officer |
C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Travis Alvin Thompson |
officer: Chief Accounting Officer |
C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS |
| Alistair Milnes |
officer: Chief Operating Officer |
C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Kevin Lee |
director, officer: Chief Executive Officer |
C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT |
| Nicholas Keen |
officer: Chief Scientific Officer |
C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Michael Skynner |
officer: Chief Operating Officer |
C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT |
| Alethia Young |
officer: Chief Financial Officer |
C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
| Lee Kalowski |
officer: President and CFO |
C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Santiago Arroyo |
officer: Chief Development Officer |
C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
| Dominic Smethurst |
officer: Chief Medical Officer |
C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Pierre Legault |
director |
P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312 |
| Kate Bingham |
director |
1365 MAIN STREET, WALTHAM MA 02451 |
| Jose-carlos Gutierrez-ramos |
director |
C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
| Plc Glaxosmithkline |
director, 10 percent owner |
980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
| Veronica Gh Jordan |
director |
C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098 |
Bicycle Therapeutics (Bicycle Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCYC has been successfully added to your